Thursday, May 31, 2012

Theralase Establishes Middle East Distribution Network


Theralase Executes Distribution Agreement with Large Middle East Medical Distributor to Sell Therapeutic Lasers

Toronto, Ontario, Canada – May 30, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that it has entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria. The current term of the agreement specifies minimum performance criteria of $USD 5 million ramping up over the next 5 years with exclusivity extended into further 5 year terms with annual performance criteria.

Roger Dumoulin-White, President and CEO of Theralase Inc. stated that “MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts. The Middle East represents a population of 384 million, located in 17 countries with a total GDP of approximately $2.3 trillion and a medical device market that exceeds $5 billion annually according to 2009 statistics. MediQu has established a distribution network that provides sales, marketing and service coverage to customers in 16 of those countries, allowing Theralase Arabia the ability to market, sell and service the Theralase brand of therapeutic medical lasers to this lucrative market. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.”

Roger Dumoulin-White, President & CEO of Theralase went on to say, “Theralase has provided initial training to MediQu’s sales, technical and clinical personnel at our inaugural launch into the region at the 4th Biennial Emirates Physiotherapy Conference held in Dubai, United Arab Emirates on May 20 and 21, 2012.” He added, “We are currently negotiating with a number of other medical device distributors worldwide who have expressed an interest in marketing, selling and servicing the Theralase brand of superpulsed laser technology in their respective countries.”

Mr. Mohamed ALNabulsi, Project and Sales Manager of MediQu stated, “We were impressed with Theralase’s superpulsed laser system from the beginning and the dominance of the Theralase brand over the other competitive products we investigated. Theralase’s unrivalled scientific and clinical knowledge on the subject of therapeutic lasers was refreshing given the fact that most competitors we spoke to lacked the same understanding of the science. The Theralase technology was the only product on the market that we found that could activate all three known cellular pathways and provide a depth of penetration of four inches into tissue, promoting cellular regeneration at the source of tissue injury.  Initial testing at our key medical facilities in Jordan has been exceptional, with all patients treated experiencing significant pain relief, substantial inflammation reduction and accelerated healing. We are delighted to partner with Theralase to roll-out this technology to the rest of the Middle East countries we service. We have long term relationships with numerous major hospitals, medical clinics and doctors in the region and will be able to proactively promote the Theralase product line immediately. Alternative medicine is embraced in the Middle East and we feel confident that Theralase’s leading edge technology will be accepted and adopted at all levels of government and private medicine.”

About MediQu:
MediQu is the commercial trademark for Fatima for Medical device company servicing 16 countries in the Middle East region. MediQu possesses significant experience regarding sales, service, regional requirements and trade regulations of the various countries in which it does business. In addition, MediQu has built strong connections at the government, commercial and medical levels enabling it to generate strong sale leads, participate in government tenders and clearly communicate the clinical advantage of its products over other competitive products allowing it to dramatically increase market share of its represented products in the region.

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         
President and CEO                                                                                                  
416-447-8455 ext. 225                                                                              

Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com                                                                         

Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262

Arkady Mandel
Chief Scientific Officer
416-447-8455 ext. 242

Mohamed ALNabulsi
Manager
Theralase Arabia
+962 77777 30004

Tuesday, May 29, 2012

Theralase to Present at BioFinance 2012 Life Sciences Conference



Toronto, Ontario – May 29, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that Roger Dumoulin-White, President and CEO will present the latest corporate information at the BioFinance 2012 conference being held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada which showcases more than 60 diverse life science companies and the investment opportunities that they present. BioFinance 2012 also features 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation will take place Wednesday, May 30th at 3:00 pm in Company Presentation Room 1 at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase will present on the strategic direction and recent accomplishments of the company followed by a short Q&A period and longer one-on-one meeting period.

In other news, Mr. Dumoulin-White was recently interviewed on the TV show “The Next Biggest Winner” which is due to air on Ichannel on Tuesday, June 5th at 7:30pm.  The Ichannel has over 1.3 million affluent Canadian subscribers who look to its business programming for investment opportunities. For a sneak preview, please visit http://youtu.be/y8VT6Rwp_gY


About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is internationally approved in the safe and effective treatment of pain, inflammation and for the regeneration of tissue in neural muscular skeletal conditions in both humans and animals. Theralase is also researching and developing patented Photo Dynamic Compound (PDC) technology that is focused at targeting and destroying specific cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         
President & CEO                                                                                       
416-447-8455 ext. 225                                                                              

Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com

Friday, May 18, 2012

The Science of Laser Therapy and Clinical Applications


The Science of Laser Therapy and 

Clinical Applications


Register today for the webinar presentation to learn more about The Science of Laser Therapy and Clinical Applications.

 

Below are topics that will be covered in the webinar:

1.     How does Laser Therapy work?
2.     Effects of wavelength and power on the therapeutic outcome.
3.     Application and patient benefits.
4.     Return on investment and clinical benefits.

Space is limited.

Reserve your Webinar seat now at:

 

 

Title: The Science of Laser Therapy and Clinical Applications

Date: Thursday, May 24, 2012

Time: 2:00 PM - 3:00 PM EST


Regards,
The Theralase Team

Links

Tuesday, May 15, 2012

Laser Therapy in an Injury Rehabilitation Clinic


Tuesday, May 29, 2012 1:00 PM - 2:00 PM EDT

Webinar Registration

Below are a few items that will be covered in the Webinar:
Learn how laser can be used by a multidisiplinary rehab team of health providers.
Review common treatments and laser protocols for chronic and acute injuries.
Gain valuable tips on billing for laser through 3rd party payers.
* 
* 
*  
* 
* 
* 
* 
* 
* 
* 

Webinar organizers are prohibited from soliciting confidential personal information (credit card information, social security numbers, etc.) in the registration form. This questionnaire is not intended to handle sensitive data.
* 
* Indicates a required field
By clicking the "Register Now" button you submit your information to the Webinar organizer, who will use it to communicate with you regarding this event and their other services.

Monday, May 14, 2012

Natural Alternatives for Mosquito Management


From The American Chiropractic Association (ACA)

The summer months are upon us—sunshine, Bar-B-Qs, and …mosquitoes! With reports of mosquito-carried diseases such as West Nile Virus, which killed 124 people in 2007,1 many consumers turn to bug repellants available on the market. Some sprays, however, carry insecticides such as DEET, Permethrin and Picaridin, and may do more harm than good to human health.
According to the Department of Health and Human Services and the Pesticide Information Profile Extension Toxicology Network, DEET has the potential to cause rashes, breathing difficulties, neurotoxic effects, and even death, especially in susceptible individuals and those overusing the chemical. Studies have also shown that the chemical is transported from the skin to all organs of the body, enters the brain, can be transferred to babies via breast milk, and can even reach the fetus.2, 3
What other options are available?
With studies and stories documenting the negative effects of DEET and other insecticides, consider other options for deterring mosquitoes and other pests. According to the Centers for Disease Control and Prevention, bug repellants using oil of lemon eucalyptus as their main ingredient, such as Repel Lemon Eucapyptus insect repellant, were found to provide similar protection to those using low concentrations of DEET.4
Several other options also use a more natural and traditional approach to repelling mosquitoes and other pests such as ticks and flies:
Product
Instructions
Bite BlockerTM
Using soybean oil, coconut oil, and geranium oil, this product has been shown to keep bugs away for an average of 95 minutes. Several options, including formulas for kids and pets, are available in retail stores and online at www.homs.com.5
Burts Bees Herbal Insect RepellantTM
Eucalyptus and lemongrass repel mosquitoes in this oil that is rubbed onto the skin.
Essential oils: lemon eucalyptus, cedar wood, lemongrass, rosemary, clove, frankincense and peppermint
Dilute 10 drops of essential oil to 2 tablespoons of carrier oil (such as grape seed or vegetable oil) to prevent skin irritation that may occur from using the concentrated oil directly on your skin.
Neem oil:
Neem Aura Naturals Bug Disenchanter, Neem Tree Farms Botanical Outdoor Gel or Spray
Long seen as a solution to many health problems, Neem oil can also keep bugs at bay. Current research classifies Neem oil as relatively non-toxic, with even high amounts not causing problems. Caution is recommended for women of child bearing age and families trying to conceive.6
Catnip oil: Nature’s Herbal Mosquito & Insect Shield
Catnip oil has been shown by the American Chemical Society and USDA to be nearly as effective as DEET in repelling bugs without the harmful side effects.7
What else can I do?
To manage mosquitoes and other pests in your yard, take the following precautions:
  • Plant insect-repelling plants in your garden. Marigolds, geraniums, catnip, citronella grass, and mosquito plants naturally keep bugs away and look beautiful in your garden. Peppermint, lemon balm (citronella), rosemary, thyme, and other herbs also have mosquito-repelling properties. You can also crush the leaves of these plants to release the oils and put them in alcohol to make an insect-repelling spray.
  • Burn sandalwood sticks in your yard.
  • Eliminate standing water from your yard and neighborhood—this is where mosquito eggs flourish and eventually hatch.
  • Don’t wear lotions and perfumes while outdoors—the scents often attract mosquitoes and flies.
  • Burn citronella candles in outside areas with low wind.
  • Keep screens in doors and windows in good condition and sealed around the perimeter so mosquitoes and flies cannot enter the house.